Duke University: Melanoma trials

The registry lists 13 Melanoma studies with Duke University as lead sponsor. 2 are open to participants now and 2 have results posted.

Phase 1 10Phase 2 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• IL-17 Blockade to Decrease irAEs (REPLAY)RecruitingNCT07237594Phase 1
• A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint TherapyRecruitingNCT05077137Phase 1
• Symptom Management for YA Cancer SurvivorsCompletedNCT04035447Not applicableResults posted
• Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced MelanomaTerminatedNCT00673361Phase 2Results posted
• Understanding Immunotherapy Resistance Mechanisms in Advanced MelanomaCompletedNCT02694965
• Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity MelanomaCompletedNCT02115243Phase 1
• A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic MelanomaWithdrawnNCT02068079Phase 1
• A Pilot Study of Ipilumimab and Radiation in Poor Prognosis MelanomaCompletedNCT01996202Phase 1
• Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic MelanomaTerminatedNCT01216436Phase 1
• A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant MelanomaWithdrawnNCT00661336Phase 1
• Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or LegCompletedNCT00565968Phase 1
• Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor RemovalCompletedNCT00003229Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain TumorsCompletedNCT00002754Phase 1